Ana Sureda

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 389 citations · Full text

Medicine, Hematology, Oncology +15

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

José Antonio Pérez‐Simón, Panagiotis Kottaridis, Rodrigo Martino et al. · Blood · 2002 · 244 citations · Full text

Life Sciences, Hematology, Immunology +16

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

Juan José Lahuerta, Joaquín Martínez‐López, Javier de la Serna et al. · British Journal of Haematology · 2000 · 107 citations · Full text

Medicine, Hematology, Oncology +14

Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation

José Antonio Pérez‐Simón, Rodrigo Martino, Adrían Alegre et al. · British Journal of Haematology · 2003 · 103 citations

Medicine, Immunology, Oncology +15